Skip to main content

Zentalis Pharmaceuticals, Inc.

corporate_fare Company Profile

Zentalis Pharmaceuticals, Inc.

ZNTL·NASDAQ·Life Sciences·CIK 0001725160

The company is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), an investigational WEE1 inhibitor, for patients with ovarian cancer and other tumor types. Azenosertib has demonstrated anti-tumor activity as a single agent across multiple tumor types in clinical trials. The company is currently advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, may support an accelerated approval, subject to U.S. Food and Drug Administration (FDA) review. The company exclusively in-licenses or solely owns worldwide development and commercialization rights to azenosertib. Its strategy includes rapidly advancing azenosertib as a monotherapy toward first regulatory approval in Cyclin E1-positive PROC. In January 2025, clinical data showed an objective response rate (ORR) of over 30% and a manageable safety profile in patients with Cyclin E1-positive PROC who received azenosertib at 400 mg QD 5:2. Enrollment in Part 2a of the Phase 2 DENALI clinical trial was completed in 2025, with a topline readout anticipated by year end 2026. The company also plans to advance the development of azenosertib outside of Cyclin E1-positive PROC, as resources allow.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZNTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for ZNTL spans 8-K, 4, 424B5, DEFA14A.

Recent high-impact activity:

  • Zentalis Q3: $228.9M Cash Extends Runway to 1H 2028, DENALI Topline Set for 1H 2027
  • Azenosertib OS Separation Confirmed: 15.9 vs 7.5 Months in Cyclin E1-Positive Ovarian Cancer
  • Azenosertib Extends Survival to 15.8 Months in Cyclin E1-Positive Ovarian Cancer
  • Zentalis' Azenosertib Shows 15.8-Month Median Survival in Cyclin E1-Positive Ovarian Cancer
  • Walters Group Buys $15.2M in Zentalis Offering, Stake Rises to 17.8M Shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$137.06M
Diluted EPS
-$1.91
Op. Cash Flow
-$125.25M
Free Cash Flow
-$125.25M
Operating Income
-$152.81M
Cash & Equivalents
$35.99M
Debt / Equity
0.00×
Shares Outstanding
69.09M sh
Source: 10-K · filed 2026-03-26 · accession 0001725160-26-000014

Short Interest & Short Volume

3.49 days to cover

FINRA reported short interest of 5,036,334 shares in ZNTL as of the October 30, 2026 settlement, a 15.9% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 46.4% of ZNTL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,036,334 shares as of October 30, 2026
Change vs prior period▼ 15.9%
Days to cover3.49 at avg daily volume of 1,442,514
Daily short volume (FINRA facilities)46.4% of 601,300 shares on November 20, 2026
5-day average short volume42.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ZNTL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.

1 recent capital raise

Offering Priced at $3.50 · Net Proceeds $75.1M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with Z →
$1.38 +1.47% today
52-week range · as of 2026-11-09 $1.21 – $6.95
Market cap
$133.64M
Volume
1.5M (1.1× avg)
3-mo avg 1.4M
Live data · 2026-11-21 09:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.38 info
Change: -$0.360 (-21%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.38 info
Change: -$0.930 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.38 info
Change: -$0.905 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.38 info
Change: -$0.730 (-35%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.38 info
Change: -$2.44 (-64%) info
Market Cap: $133.642M info
ZNTL
Aug 14, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $1.38 info
Change: -$2.16 (-61%) info
Market Cap: $133.642M info
ZNTL
Aug 14, 2026, 4:09 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $1.38 info
Change: -$2.16 (-61%) info
Market Cap: $133.642M info
ZNTL
Aug 14, 2026, 6:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.69
Real-time Price: $1.38 info
Change: -$2.31 (-63%) info
Market Cap: $133.642M info
ZNTL
Aug 13, 2026, 10:24 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.75
Real-time Price: $1.38 info
Change: -$2.37 (-63%) info
Market Cap: $133.642M info
ZNTL
Aug 13, 2026, 4:37 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.65
Real-time Price: $1.38 info
Change: -$2.27 (-62%) info
Market Cap: $133.642M info
ZNTL
Aug 06, 2026, 5:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.80
Real-time Price: $1.38 info
Change: -$3.42 (-71%) info
Market Cap: $133.642M info
ZNTL
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.80
Real-time Price: $1.38 info
Change: -$3.42 (-71%) info
Market Cap: $133.642M info
ZNTL
May 27, 2026, 4:16 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $1.38 info
Change: -$2.64 (-66%) info
Market Cap: $133.642M info
ZNTL
May 27, 2026, 4:08 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $1.38 info
Change: -$2.64 (-66%) info
Market Cap: $133.642M info
ZNTL
May 21, 2026, 5:39 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $1.38 info
Change: -$2.76 (-67%) info
Market Cap: $133.642M info
ZNTL
May 21, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $1.38 info
Change: -$2.76 (-67%) info
Market Cap: $133.642M info
ZNTL
May 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $1.38 info
Change: -$2.90 (-68%) info
Market Cap: $133.642M info
ZNTL
May 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $1.38 info
Change: -$2.90 (-68%) info
Market Cap: $133.642M info
ZNTL
May 05, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.00
Real-time Price: $1.38 info
Change: -$2.62 (-66%) info
Market Cap: $133.642M info
ZNTL
Apr 21, 2026, 10:27 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $1.38 info
Change: -$2.64 (-66%) info
Market Cap: $133.642M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets